Balkrishna Industries Board Approves Q3 2026 Results, Declares ₹4 Interim Dividend

Balkrishna Industries’ Board approved the unaudited financial results for Q3 2026, which ended on December 31, 2025. The board also declared an interim dividend of ₹4 per equity share. The dividend will be credited/dispatched within 30 days, with a record date of February 2, 2026. Results are compliant with Regulations 33 and 52 of the SEBI Listing Regulations.

Q3 2026 Financial Highlights

The Board of Directors of Balkrishna Industries has approved the unaudited financial results for the quarter and nine months ended December 31, 2025. These results, both standalone and consolidated, comply with Regulations 33 and 52 of the SEBI Listing Regulations.

Dividend Declaration

The Board has declared a 3rd interim dividend of ₹4 per Equity Share (200%) on equity shares of ₹2 each for the financial year 2025-26. The dividend payment will be processed within 30 days from the declaration date, with a record date set for February 2, 2026.

Financial Performance Overview (Standalone)

Key figures from the standalone results (₹ in Crores) for the quarter ended December 31, 2025:

  • Revenue from Operations: ₹2729.69
  • Total Income: ₹2806.44
  • Profit Before Tax: ₹483.39
  • Profit for the Period: ₹384.03

Financial Performance Overview (Consolidated)

Key figures from the consolidated results (₹ in Crores) for the quarter ended December 31, 2025:

  • Revenue from Operations: ₹2736.79
  • Total Income: ₹2814.20
  • Profit Before Tax: ₹491.06
  • Profit for the Period: ₹382.15

Additional Key Ratios

Key financial ratios as of December 31, 2025, include:

  • Debt-Equity Ratio: 0.34 (Standalone & Consolidated)
  • Debt Service Coverage Ratio: 4.40 (Standalone), 4.47 (Consolidated)
  • Interest Service Coverage Ratio: 78.20 (Standalone), 80.64 (Consolidated)

Disclosure on Usage of Proceeds

Balkrishna Industries confirms that the proceeds from the Non-convertible securities for the quarter ended December 31, 2025, were used for the intended purposes. The company adheres to the listing conditions as specified.

  • Scrip Code 730703 commercial paper: allotted December 4, 2025, with redemption on March 2, 2026.
  • Scrip Code 730801 commercial paper: allotted December 18, 2025, with redemption on March 13, 2026.

Source: BSE

Previous Article

MedPlus Drug License Suspension for Andhra Pradesh Store

Next Article

Five Star Business Finance Q3FY26 Financial and Operational Performance